Sputnik V COVID-19 vaccine

Kazakhstan becomes the first country outside Russia to authorize Sputnik M vaccine for adolescents

Retrieved on: 
Tuesday, February 22, 2022
Infection, Sputnik 1, Population, Lazzaro Spallanzani National Institute for Infectious Diseases, Ministry of Health (Russia), Ministry, Sputnik Light, Russian Direct Investment Fund, Equity, Republic, Ageing, Vaccine, Immunoglobulin G, VNA, Sputnik V COVID-19 vaccine, Vaccination, Communications satellite, Omicron, RDIF, Pfizer, COVID

Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.

Key Points: 
  • Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.
    In contrast with some international producers offering their vaccines in the same dosage for both adults and adolescents, the Gamaleya Center has developed Sputnik M specifically for adolescents.
  • Sputnik M is a two-shot vaccine based on the same human adenoviral vectors platform, which is safe and has been widely studied for over 30 years.
  • The only difference between Sputnik M and Sputnik V is a lower concentration of viral particles per dose: Sputnik M for adolescents has 5 times less concentration in comparison with the original Sputnik V in both shots.
  • Russian Ministry of Health registered Sputnik M on November 24, 2021 based on data from clinical trials confirming the high safety and immunogenicity profile of Sputnik M among adolescents.

Sputnik V is Most Used Vaccine in Mexico City, Over 3 Million People Already Given the Russian Vaccine

Retrieved on: 
Sunday, February 13, 2022
Sputnik V COVID-19 vaccine, Infection, Lazzaro Spallanzani National Institute for Infectious Diseases, Vaccine, RNA transfection, LINK, Sputnik 1, Safety, Director general, CDMX, Technology, AstraZeneca, Sputnik Light, VNA, Population, Publication, Ageing, Immunoglobulin G, Myocarditis, Pericarditis, Vaccination, City, Communications satellite, COVID, Omicron, Pfizer

The first component of Sputnik V (Sputnik Light) is also increasingly used in the city's revaccination campaign as a booster.

Key Points: 
  • The first component of Sputnik V (Sputnik Light) is also increasingly used in the city's revaccination campaign as a booster.
  • (LINK: https://www.milenio.com/politica/comunidad/sputnik-v-vacuna-rusa-utiliza... )
    City of Mexico will also extend the use of the first component of Sputnik V (Sputnik Light) as a booster for 30-39 aged group from February 14.
  • Sputnik V creates stronger and longer lasting immune response against COVID (including the Omicron variant) than many other vaccines, which is further strengthened by Sputnik Light booster.
  • Sputnik Light is based on human adenovirus serotype 26 and is the first component of Sputnik V vaccine.

Sputnik V vaccine granted full permanent approval in Russia

Retrieved on: 
Friday, February 4, 2022
Safety, List of health departments and ministries, Russian Direct Investment Fund, Coronavirus, Infection, COVID-19, Vaccination, Sputnik Light, Population, Pericarditis, V, Lazzaro Spallanzani National Institute for Infectious Diseases, Sputnik V COVID-19 vaccine, Vaccine, Immunoglobulin G, Equity, AstraZeneca, EUA, Myocarditis, Pharmaceutical industry, Omicron, Pfizer, RDIF

MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry. It had previously held temporary emergency use authorization (EUA) from the Russian regulator.

Key Points: 
  • MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry.
  • Sputnik V was authorized on August 11, 2020, becoming the world's first vaccine against COVID-19 to be granted emergency use authorization.
  • Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
  • Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V).

Venezuela received 7 mn doses of Sputnik Light booster in the biggest one-time global delivery of the one-shot Russian vaccine

Retrieved on: 
Tuesday, December 21, 2021
Hospital, Sputnik V COVID-19 vaccine, Vaccination, Pericarditis, Gamaleya Research Institute of Epidemiology and Microbiology, Infection, Sputnik 1, Technology, Equity, RNA transfection, AstraZeneca, City, Vaccine, Epitope, Myocarditis, Ministry, Coronavirus, Gamaleya, VNA, Sputnik Light, Russian Direct Investment Fund, RDIF, Delta, Omicron

MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.

Key Points: 
  • MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.
  • Sputnik Light is based on human adenovirus serotype 26 (the first component of Sputnik V).
  • Recent preliminary study announced by Gamaleya Institute showed that Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron.
  • Sputnik V standalone also induces robust neutralizing antibody response to Omicron variant, which is further strengthened by Sputnik Light booster.

Recommendations of EMA and ongoing combo studies support mix&match approach pioneered by Sputnik team to fight COVID

Retrieved on: 
Tuesday, December 7, 2021
EMA, Research, Population, Mortality, Safety, Coronavirus, RNA transfection, Vaccine, Russian Direct Investment Fund, CEO, COVID, Vaccination, 2020 European Medicines Agency cyberattack, Sputnik Light, Antibody, RDIF, European Medicines Agency, Pfizer–BioNTech COVID-19 vaccine, AstraZeneca, Immunity, Infection, Ministry, Sputnik V COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry

Thus efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines.

Key Points: 
  • Thus efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines.
  • Sputnik Light as a booster helps other vaccines to increase their efficacy and has a high safety profile.
  • A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated Sputnik Light is an effective universal booster.
  • RDIF reiterates its offer to producers and countries to join efforts in protecting population through supplies of Sputnik V and Sputnik Light and their combination with other vaccines."

RDIF ready to provide the one-shot Sputnik Light vaccine and Sputnik M vaccine (for adolescents) as it develops strategic cooperation with partners in India to fight COVID

Retrieved on: 
Monday, December 6, 2021
Coronavirus, CEO, Serum Institute of India, Population, Hospital, Partnership, Equity, Panacea Biotec, Oxford–AstraZeneca COVID-19 vaccine, AstraZeneca, Ageing, Ministry, Vaccine, Vaccination, List of health departments and ministries, Sputnik 1, Immunity, Russian Direct Investment Fund, Sputnik Light, Sputnik V COVID-19 vaccine, Gamaleya, Infection, COVID, Pharmaceutical industry

Today India is the leading production hub for Sputnik V and Sputnik Light vaccines.

Key Points: 
  • Today India is the leading production hub for Sputnik V and Sputnik Light vaccines.
  • A major partner of RDIF, Dr. Reddy's Laboratories, has conducted additional clinical trials of Sputnik Light in India.
  • It has become a new member of the Sputnik vaccines family and is offered to international markets joining Sputnik V and Sputnik Light.
  • We are ready to offer the Sputnik Light vaccine and the Sputnik M vaccine for adolescents to support strong herd immunity in India and continue saving millions of lives."

The one-shot Sputnik Light vaccine authorized in UAE as a universal booster shot

Retrieved on: 
Tuesday, November 30, 2021
Coronavirus, Hospital, Equity, Ageing, Ministry, Vaccine, Vaccination, Sputnik 1, List of health departments and ministries, Sputnik Light, Sputnik V COVID-19 vaccine, Gamaleya, Infection, Pharmaceutical industry

Sputnik Light vaccine is based on human adenovirus serotype 26 which is the first component of the Sputnik V vaccine.

Key Points: 
  • Sputnik Light vaccine is based on human adenovirus serotype 26 which is the first component of the Sputnik V vaccine.
  • In January 2021 UAE's regulatory authorities also authorized the two-dose Sputnik V. Both Sputnik Light and Sputnik V vaccines have been approved by MOHAP under the emergency use authorization procedure.
  • One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster.
  • Paraguay's Ministry of Health also found Sputnik Light to be 93.5% effective during the country's ongoing vaccination campaign.

Laos becomes the 20th country to authorize the one-shot Sputnik Light vaccine

Retrieved on: 
Tuesday, November 23, 2021
People, Coronavirus, Democratic republic, Hospital, Equity, Ministry, Vaccine, Vaccination, Sputnik 1, List of health departments and ministries, Sputnik Light, Sputnik V COVID-19 vaccine, Russian Direct Investment Fund, Gamaleya, Infection

Thus Laos has become the 20th country to register Sputnik Light.

Key Points: 
  • Thus Laos has become the 20th country to register Sputnik Light.
  • Sputnik Light vaccine is based on human adenovirus serotype 26, which is the first component of the Sputnik V vaccine.
  • Both Sputnik Light and Sputnik V vaccines have been approved under the emergency use authorization procedure.
  • One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster.

A study in Belarus on Sputnik V shows high safety profile and 96.3% efficacy against COVID after vaccination of over 1.2 million people

Retrieved on: 
Wednesday, November 17, 2021
Population, Safety, Ministry of Health (Bahrain), Sputnik Light, Sputnik V COVID-19 vaccine, Ministry, Equity, Coronavirus, Technology transfer, MedRxiv, Russian Direct Investment Fund, Belmedpreparaty, RUE, Vaccination, Republic, Pharmaceutical industry, Vaccine

MOSCOW, Nov. 17, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the Russian Sputnik V coronavirus vaccine has demonstrated 96.3% efficacy and high safety profile based on new study of vaccinated individuals in the Republic of Belarus.

Key Points: 
  • High efficacy of Sputnik V is confirmed on the background of Delta variant being prevailing in Belarus since July 2021.
  • Study also confirmed high safety profile of Sputnik V:
    Reported adverse events following vaccination were mild or moderate;
    No deaths related to the vaccination.
  • Belarus was the first foreign country to register Sputnik V and use it for vaccination of the population.
  • In April 2021 the single-dose Sputnik Light vaccine (the first component of Sputnik V based on human adenovirus serotype 26) was also registered in Belarus.

A study published in The Lancet confirms the one-shot Sputnik Light vaccine has a high safety profile and induces a strong humoral and cellular immune response both in the seronegative and seropositive groups

Retrieved on: 
Wednesday, November 3, 2021
Safety, Infection, Volunteering, City, Vaccine, Sputnik V COVID-19 vaccine, Vaccination, Sputnik Light, Russian Direct Investment Fund, Ministry, Gamaleya, Equity, List of health departments and ministries, Hospital, AstraZeneca, COVID, Sputnik 1, Coronavirus, Pharmaceutical industry

The article in The Lancet is available at:

Key Points: 
  • The article in The Lancet is available at:
    The study on safety, tolerability and immunogenicity of the Sputnik Light vaccine has confirmed that the vaccine induces strong humoral and cellular immune response both in the seronegative and seropositive groups.
  • One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster.
  • Sputnik Light has been authorized in more than 15 countries with the registration process ongoing in a further 30 countries.
  • The data from Argentina also demonstrated high safety profile of using Sputnik Light in combinations with all other vaccines with no serious adverse events following the vaccination in any combinations.